Alpha 2-adrenergic receptors in the human cell line, HT29. Characterization with the full agonist radioligand [3H]UK-14,304 and inhibition of adenylate cyclase

JT Turner, C Ray-Prenger and DB Bylund

We have characterized the alpha 2-adrenergic receptor in membranes from the human colonic adenocarcinoma cell line, HT29, using the recently introduced alpha 2-agonist 5-bromo-6-[2-imidazolin-2-yl- amino]quinoxaline [( 3H]UK-14,304), two other radioligands, and a series of adrenergic agonists and antagonists. We also investigated alpha 2-agonist inhibition of HT29 cell adenylate cyclase and reversal of inhibition by alpha-adrenergic antagonists. [3H] Yohimbine saturation experiments indicated a single class of sites with a KD of 0.61 nM which agreed with the kinetically determined KD of 0.62 nM. Computer analysis of kinetic and saturation experiments with [3H]UK- 14,304 revealed two classes of sites. From the saturation data, one site had high affinity for the radioligand (0.14 nM) and comprised 33% of the total number of sites, whereas the other site had lower affinity (6.1 nM). The total number of sites labeled by [3H]UK-14,304 (360 fmol/mg of protein) was approximately equal to the number of sites labeled by [3H]yohimbine (330 fmol/mg), whereas [3H]para-aminoclonidine labeled fewer sites of a single class. Rank order potencies of adrenergic agonists and antagonists obtained from competition binding assays indicated that: the same receptors were labeled by the three radioligands, and the receptors were of the alpha 2 subtype. UK-14,304 and epinephrine inhibited forskolin- and vasoactive intestinal peptide- stimulated adenylate cyclase in a dose-dependent manner up to 32%. Inhibition of the enzyme was reversed by yohimbine and, less potently, by phentolamine and prazosin in a dose-dependent manner. The HT29 cell line appears to be a useful model system for the investigation of the regulation and mechanism of action of alpha 2-adrenergic receptors in human tissues.

Volume 28, Issue 5, pp. 422-430, 11/01/1985
Copyright © 1985 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				A. B. Fawzi, D. Macdonald, L. L. Benbow, A. Smith-Torhan, H. Zhang, B. C. Weig, G. Ho, D. Tulshian, M. E. Linder, and M. P. Graziano SCH-202676: An Allosteric Modulator of Both Agonist and Antagonist Binding to G Protein-Coupled Receptors Mol. Pharmacol., January 1, 2001; 59(1): 30 - 37. [Abstract] [Full Text]

				A. Russell and S. Watts Vascular Reactivity of Isolated Thoracic Aorta of the C57BL/6J Mouse J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 598 - 604. [Abstract] [Full Text]

				W.-N. Tian, D. D. Miller, and R. C. Deth Bidirectional Allosteric Effects of Agonists and GTP at alpha 2A/D-Adrenoceptors J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 664 - 671. [Abstract] [Full Text]

				Y. Zhu and J. L. Yakel Modulation of Ca2+ Currents by Various G Protein-Coupled Receptors in Sympathetic Neurons of Male Rat Pelvic Ganglia J Neurophysiol, August 1, 1997; 78(2): 780 - 789. [Abstract] [Full Text] [PDF]

				D. E. Handy and H. Gavras Evidence for Cell-Specific Regulation of Transcription of the Rat {alpha}2A-Adrenergic Receptor Gene Hypertension, April 1, 1996; 27(4): 1018 - 1024. [Abstract] [Full Text]